HIGHLIGHTS
- who: Reimbursement recommendations et al. from the evidence in Canada have published the research work: Reimbursement recommendations for cancer drugs supported by phase II evidence in Canada, in the Journal: (JOURNAL)
- what: The perc accepts cancer drug submissions with phase ii evidence for review, and positive or conditional recommendations for reimbursement are associated with substantial clinical benefit, presence of unmet need, patient alignment, and lack of feasibility of a phase iii trial.
- how: The authors conducted multivariable analysis with logistic regression for these variables feasibility of phase iii study hematologic indication and unmet . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.